SYDNEY, Sept. 02, 2026 (GLOBE NEWSWIRE) — XGEN, the operating brand of GenEmbryomics Limited (Nasdaq: XGEN) and the global leader in embryo and parent whole genome sequencing for in vitro fertilization (IVF), today announced the appointment of David Hoffman, M.D. and Professor Mark I. Evans, M.D. to the Company’s Board of Directors. Both gentlemen join as Executive Directors and, additionally, as Medical Directors of XGEN, effective 12 July 2026.
The appointments further strengthen XGEN’s world-class scientific and clinical leadership at a pivotal moment as the Company advances its flagship test, Panacea-GenomeScreen™, the world’s first preimplantation genetic testing (PGT) solution powered by whole genome sequencing (PGT-WGS), capable of screening for more than 3,200 severe and fatal genetic diseases in IVF embryos at >30x whole-genome coverage, including mutations in genes that can adversely affect pregnancy and lead to pregnancy loss.
Panacea-GenomeScreen™ is XGEN’s deep-sequencing test for complex and mutation-directed PGT-M casework. In 2026, the Company expanded its embryo-testing portfolio with XGEN PGT-X™, launched at PGDIS in Shanghai and priced at US$499 (RRP) per embryo. Designed to complement routine PGT-A, PGT-X brings broader genomic interrogation into mainstream IVF workflows, while Panacea-GenomeScreen™ provides the depth required for more complex inherited-disease cases. Together, the two tests extend XGEN’s technology from routine embryo assessment through to highly specialised reproductive genetics. The clinical backgrounds of David Hoffman and Mark I. Evans align closely with that breadth: Hoffman brings decades of experience in assisted reproduction and IVF, while Evans brings internationally recognised expertise in prenatal diagnosis, medical genetics and reproductive medicine.
XGEN is an international business headquartered in Sydney, Australia, with a growing clinical and commercial presence across major global IVF markets. XGEN works with genetics laboratories and IVF providers across North America, Europe, the Middle East and Asia, combining its Australian scientific and operational base with an international network of clinical, laboratory and commercial partners. The appointments of Hoffman and Evans significantly deepen the Company’s clinical leadership in the United States while complementing an already international Board, scientific network and commercial footprint.
“We are delighted to welcome David and Mark to the XGEN Board. They bring extraordinary depth of clinical expertise, scientific credibility, and global networks directly relevant to our mission. Together, they represent decades of leadership at the forefront of reproductive medicine and genetics – precisely the fields in which XGEN is driving transformative change. Their appointment sends a clear signal to the market, to clinicians, and to patients worldwide about the calibre of science underpinning XGEN.” – Paul K. M. Viney, Chairman, XGEN
DAVID HOFFMAN, M.D.
Executive Director & Medical Director
David Hoffman, M.D. is a board-certified Reproductive Endocrinologist with more than 45 years of experience in the diagnosis and treatment of infertility. He received his medical degree from Temple University School of Medicine in 1978, completed his residency in Obstetrics & Gynecology at LAC/USC Medical Center, and undertook his fellowship in Reproductive Endocrinology and Infertility (REI), also at LAC/USC Medical Center, in 1984.
Hoffman went on to establish the IVF programme at Northwestern University, where he served as Director of the Division of Reproductive Endocrinology and Infertility. In 1989 he joined IVF Florida Reproductive Associates, one of the largest and most respected fertility practices in the United States, where he has built a distinguished career spanning more than three decades. He is experienced across all areas of assisted reproductive technology (ART), including IVF, embryo transfer, laparoscopic and endoscopic surgery, recurrent miscarriage, and the management of endometriosis. He is board-certified in both Obstetrics & Gynecology and Reproductive Endocrinology and Infertility.
Among his leadership distinctions, Hoffman has served as President of the Society of Assisted Reproductive Technologists (SART) and received the Distinguished Service Award from the American Society for Reproductive Medicine (ASRM) in 2006. He has published more than 65 peer-reviewed abstracts, articles, and book chapters and has presented his research at major international conferences including ESHRE and the World Congress on IVF.
“XGEN is doing something genuinely different in the fertility space. Panacea-GenomeScreen™ has the potential to fundamentally change how we evaluate embryos and give families the confidence that comes from truly comprehensive genetic insight. I am honoured to be joining the Board at this exciting stage of the Company’s development.” – David Hoffman, M.D.
PROFESSOR MARK I. EVANS, M.D.
Executive Director & Medical Director
Professor Mark I. Evans is one of the world’s most celebrated figures in prenatal diagnosis, obstetrics, and reproductive genetics, with a career spanning more than four decades at the forefront of the field. He is currently Professor of Obstetrics, Gynecology, and Reproductive Sciences at the Icahn School of Medicine at Mount Sinai, New York, and Visiting Professor at the Yong Loo Lin School of Medicine, National University of Singapore.
Professor Evans graduated magna cum laude with special honours from Tufts University in 1973, earned his medical degree with distinction in research from SUNY Downstate Medical Center in 1978, completed his Obstetrics & Gynecology residency at the University of Chicago, and undertook a Medical Genetics fellowship at the National Institutes of Health (NIH). He is double board-certified in Obstetrics & Gynecology and Medical Genetics.
He spent seventeen years at Wayne State University, rising to become the Charlotte B. Failing Distinguished Professor and Chairman of Obstetrics & Gynecology, Professor of Molecular Medicine and Genetics, and Professor of Pathology. He subsequently served as Professor and Chairman of Obstetrics & Gynecology at MCP Hahnemann University before returning to New York, where he is Founder and Director of Comprehensive Genetics, PLLC, providing advanced prenatal diagnosis and fetal therapy to patients across the United States and internationally.
Professor Evans is recognised as a pioneer across multiple areas of reproductive medicine. His contributions include the development of chorionic villus sampling (CVS) techniques, screening methods for chromosomal abnormalities, and in utero fetal muscle biopsy for Duchenne Muscular Dystrophy. He performed the world’s first successful in utero stem cell transplant to cure a baby with severe combined immunodeficiency (SCID), and was part of the pioneering team that performed the first open fetal surgery for diaphragmatic hernia. He developed the nation’s largest AFP screening programme (Quest Diagnostics) and co-developed nuchal translucency screening training worldwide with the Fetal Medicine Foundation and Perkin Elmer.
Professor Evans has authored or co-authored more than 1,200 scientific publications and 30 textbooks. He is Founder and President of the Fetal Medicine Foundation of America (FMFA) and President of the International Fetal Medicine and Surgery Society Foundation (IFMSS). He has been elected President of the International Fetal Medicine and Surgery Society on two occasions and served as President of the Central Association of Obstetricians and Gynecologists.
His honours include the Pioneer Award from the International Society for Prenatal Diagnosis (2023), the Lifetime Achievement Award from the International Fetal Medicine and Surgery Society, the Albert Nelson Marquis Diamond of the Decade Award (Who’s Who in America), and the President’s Achievement Award from the Society for Gynecologic Investigation. He has been named to “Best Doctors in America” continuously since 1994.
“The science behind XGEN is compelling. Whole genome sequencing of embryos prior to implantation represents the logical next step in giving families the most complete picture of genetic health possible. I have devoted my career to advancing the ability of medicine to detect, prevent, and treat genetic disease, and XGEN’s Panacea-GenomeScreen™ platform is precisely the kind of breakthrough that will transform outcomes for IVF patients globally. I am very much looking forward to contributing to the Company’s mission.” – Professor Mark I. Evans
ABOUT XGEN
XGEN is a genomics-based company dedicated to empowering families to have healthy children by providing IVF patients and providers with unparalleled insights into embryonic genetic health. XGEN is the operating brand of GenEmbryomics Limited (Nasdaq: XGEN), an Australian company founded in 2016 and headquartered in Sydney, with its scientific and operational base in Australia. The Company has developed the world’s first whole genome sequencing-based preimplantation genetic testing platform. Its flagship test, Panacea-GenomeScreen™, delivers 30x whole-genome coverage and screens for more than 3,200 severe and fatal genetic diseases in embryos. Its companion test, XGEN PGT-X™, launched at PGDIS 2026 in Shanghai, brings embryo-genome sequencing to routine IVF as an adjunct to conventional PGT-A at US$499 (RRP) per embryo. XGEN’s proprietary bioinformatics pipeline generates comprehensive embryo genetic profiles to support optimal embryo selection, improving IVF success rates and reducing the transmission of genetic disease. The Company deploys its technology internationally, reaching IVF clinics through accredited genetics laboratory partners across North America, Europe, the Middle East, China, and Southeast Asia.
For more information, please visit www.genembryomics.com.
INVESTOR & MEDIA ENQUIRIES
Paul K. M. Viney Chairman, GenEmbryomics Limited
T: +61 411 282 401
E: support@genembryomics.com
W: www.genembryomics.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of applicable securities laws. Such statements are based on current expectations and are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied. GenEmbryomics Limited undertakes no obligation to update any forward-looking statements.
